Loading...
•
Sep 30, 2024
Alector Q3 2024 Earnings Report
Alector reported third quarter 2024 financial results and provided a business update.
Key Takeaways
Alector reported a net loss of $42.2 million, or $0.43 per share, for the quarter ended September 30, 2024. As of September 30, 2024, Alector’s cash, cash equivalents, and investments totaled $457.2 million, which is expected to fund operations through 2026.
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024
Participant baseline characteristics in pivotal INFRONT-3 Phase 3 trial suggest a representative study population for testing the effects of latozinemab in frontotemporal dementia with a progranulin gene mutation (FTD-GRN)
Cash, cash equivalents and investments totaled $457.2 million, providing runway through 2026
PROGRESS-AD, the Phase 2 trial of AL101/GSK4527226 in early Alzheimer’s disease, has reached more than one-third of its target enrollment.
Revenue by Segment
Forward Guidance
The Company continues to anticipate collaboration revenue to be between $60 million and $70 million, total research and development expenses to be between $210 million and $220 million, and total general and administrative expenses to be between $60 million and $70 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...